Percutaneous ablation of post-surgical solitary early recurrence of colorectal liver metastases is an effective "test-of-time" approach
- PMID: 33844146
- DOI: 10.1007/s13304-021-01047-x
Percutaneous ablation of post-surgical solitary early recurrence of colorectal liver metastases is an effective "test-of-time" approach
Abstract
Standard treatment of early recurrence of colorectal liver metastases (CLM) after liver resection (LR) is chemotherapy followed by loco-regional therapy. We reviewed the outcome of a different strategy ("test-of-time" approach): upfront percutaneous ablation without chemotherapy. Twenty-six consecutive patients with early solitary liver-only recurrence amenable to both resection and ablation (< 30 mm, distant from vessels) undergone "test-of-time" approach were analyzed. Early recurrence had a median size of 17 mm and occurred after a median interval from LR of 4 months. Primary efficacy rate of ablation was 100%. Five patients are alive and disease-free after a mean follow-up of 46 months. Five patients had local-only recurrence; all had repeat treatment (LR = 4; Ablation = 1) without chemotherapy. Local recurrence risk was associated with incomplete ablation of 1-cm thick peritumoral margin. The remaining 16 patients had non-local recurrence, 13 early after ablation. Overall, six (23%) patients had ablation as unique treatment and 13 (50%) avoided or postponed chemotherapy (mean chemotherapy-free interval 33.5 months). Ablation without chemotherapy of early liver-only recurrence is a reliable "test-of-time" approach. It minimized the invasiveness of treatment with good effectiveness and high salvageability in case of local failure, avoided worthless surgery, and saved chemotherapy for further disease progression.
Keywords: Liver resection for colorectal liver metastases; Local recurrence; Microwave ablation; Radiofrequency ablation; Salvage surgery; Tumor biology.
© 2021. Italian Society of Surgery (SIC).
Similar articles
-
Solitary colorectal liver metastasis: resection determines outcome.Arch Surg. 2006 May;141(5):460-6; discussion 466-7. doi: 10.1001/archsurg.141.5.460. Arch Surg. 2006. PMID: 16702517
-
Safety and Efficacy of Ultrasound-Guided Radiofrequency Ablation of Recurrent Colorectal Cancer Liver Metastases after Hepatectomy.Scand J Surg. 2015 Sep;104(3):169-75. doi: 10.1177/1457496914553147. Epub 2014 Oct 20. Scand J Surg. 2015. PMID: 25332220
-
Clinical Outcomes and Predictors in Patients With Unresectable Colorectal Cancer Liver Metastases Following Salvage Percutaneous Radiofrequency Ablation: A Single Center Preliminary Experience.Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820963662. doi: 10.1177/1533033820963662. Technol Cancer Res Treat. 2020. PMID: 33034276 Free PMC article.
-
[Diagnosis and treatment of colorectal liver metastases - workflow].Zentralbl Chir. 2008 Jun;133(3):267-84. doi: 10.1055/s-2008-1076796. Zentralbl Chir. 2008. PMID: 18563694 Review. German.
-
Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? An update.Dig Surg. 2008;25(6):445-60. doi: 10.1159/000184736. Epub 2009 Feb 12. Dig Surg. 2008. PMID: 19212117 Review.
Cited by
-
Repeat Local Treatment of Recurrent Colorectal Liver Metastases, the Role of Neoadjuvant Chemotherapy: An Amsterdam Colorectal Liver Met Registry (AmCORE) Based Study.Cancers (Basel). 2021 Oct 5;13(19):4997. doi: 10.3390/cancers13194997. Cancers (Basel). 2021. PMID: 34638481 Free PMC article.
-
Artificial Intelligence to Early Predict Liver Metastases in Patients with Colorectal Cancer: Current Status and Future Prospectives.Life (Basel). 2023 Oct 9;13(10):2027. doi: 10.3390/life13102027. Life (Basel). 2023. PMID: 37895409 Free PMC article. Review.
-
Recurrent Colorectal Liver Metastases: Upfront Local Treatment versus Neoadjuvant Systemic Therapy Followed by Local Treatment (COLLISION RELAPSE): Study Protocol of a Phase III Prospective Randomized Controlled Trial.Cardiovasc Intervent Radiol. 2024 Feb;47(2):253-262. doi: 10.1007/s00270-023-03602-y. Epub 2023 Nov 9. Cardiovasc Intervent Radiol. 2024. PMID: 37943351 Free PMC article.
-
Is precision medicine for colorectal liver metastases still a utopia? New perspectives by modern biomarkers, radiomics, and artificial intelligence.World J Gastroenterol. 2022 Feb 14;28(6):608-623. doi: 10.3748/wjg.v28.i6.608. World J Gastroenterol. 2022. PMID: 35317421 Free PMC article. Review.
References
-
- Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J (1994) Factors influencing the natural history of colorectal liver metastases. Lancet (London, England) 343(8910):1405–1410
-
- Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aguilar EA, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Arnold D et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422. https://doi.org/10.1093/annonc/mdw235 - DOI
-
- Creasy JM, Sadot E, Koerkamp BG, Chou JF, Gonen M, Kemeny NE, Balachandran VP, Kingham TP, DeMatteo RP, Allen PJ, Blumgart LH, Jarnagin WR, D’Angelica MI (2018) Actual 10-year survival after hepatic resection of colorectal liver metastases: what factors preclude cure? Surgery 163(6):1238–1244. https://doi.org/10.1016/j.surg.2018.01.004 - DOI
-
- Viganò L, Ferrero A, Tesoriere RL, Capussotti L (2008) Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol 15(9):2458–2464. https://doi.org/10.1245/s10434-008-9935-9 - DOI
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical